Eli Lilly and Incyte's eczema treatment delayed at FDA – again
The two pharmaceutical companies have been forced to announce that the FDA's processing of Olumiant as a treatment for atopic dermatitis has been delayed for a second time. This is due to questions surrounding the drug class.
BY ELIZABETH MØNSTED JOHANSEN, TRANSLATED BY CATHERINE BRETT
The US Food and Drug Administration, FDA, has again postponed its deadline for responding to Eli Lilly's application for the authorization of Olumiant, which is an eczema treatment for adults.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Eli Lilly acquires biotech firm in new insulin venture
For subscribers
.jpg&w=384&q=75)
